Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for SCY-770 (AMPK Activator) in Autosomal Dominant Polycystic Kidney Disease. The expected timing is based on the latest available company guidance and may change.
03/31/26:- Acquired PXL770 renamed SCY-770; plan Ph2 ADPKD start Q4 2026; efficacy review H2 2027. 05/11/26:- Reiterated plan for Ph2 ADPKD start Q4 2026 and early efficacy readout in H2 2027. 06/30/26:- Initiated Ph1 food-effect study; topline data expected Q3 2026; Ph2 ADPKD initiation on track Q4 2026. 08/10/26:- Reiterated Ph1 topline data in Q3 2026, Ph2 start in Q4 2026, efficacy readout H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.